Regorafenib-d3

• Description :

  Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331) . Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

• CAS Number :

  [1255386-16-3]

• Product Name Alternative :

  BAY 73-4506-d3

• UNSPSC :

  12352005

• Target :

  Autophagy; PDGFR; Raf; RET; VEGFR

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  98.0

• Solubility :

  10 mM in DMSO|DMSO : 125mg/mL (ultrasonic)

• Smiles :

  O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C(F)=C2)=C1)NC([2H])([2H])[2H]

• Molecular Formula :

  C21H12D3ClF4N4O3

• Molecular Weight :

  485.83

• References & Citations :

  [1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported